+ Follow FENOFIBRATE INTERVENTION AND EVENT LOWERING Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 411036
[Title] => Delaying diabetic retinopathy
[Summary] => The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ...
[DatePublished] => 2008-10-30 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 57893
[Title] => Treating diabetic retinopathy
[Summary] =>
[DatePublished] => 2008-04-24 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 289788
[Title] => Managing metabolic syndrome with fenofibrates
[Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome.
A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.
Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.
[DatePublished] => 2005-08-04 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
FENOFIBRATE INTERVENTION AND EVENT LOWERING
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 411036
[Title] => Delaying diabetic retinopathy
[Summary] => The results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study confirmed fenofibrate’s ...
[DatePublished] => 2008-10-30 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[1] => Array
(
[ArticleID] => 57893
[Title] => Treating diabetic retinopathy
[Summary] =>
[DatePublished] => 2008-04-24 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
[2] => Array
(
[ArticleID] => 289788
[Title] => Managing metabolic syndrome with fenofibrates
[Summary] => Fenofibrate has been shown to reduce risk of coronary events, including non-fatal heart attack and stroke, in patients with metabolic syndrome.
A study demonstrated the benefits of fenofibrate therapy in atherogenic dyslipidemia, a common risk factor for metabolic syndrome, a constellation of risk factors which also include obesity, insulin resistance and hypertension.
Atherogenic dyslipidemia is characterized by high-triglycerides, low high-density lipoprotein (HDL) and the preponderance of small low-density lipoprotein.
[DatePublished] => 2005-08-04 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
October 30, 2008 - 12:00am